Nociscan Publication Spotlight: Recent discussions on X about Aclarion, Inc. (ACON) have surged following the publication of an article on its Nociscan technology in the International Journal of Spine Surgery. Many users highlighted the AI-powered tool’s potential to improve surgical precision for back pain treatment. The stock saw a notable premarket rise, fueling further interest.
Commercial Leadership Boost: Conversations also focused on Aclarion’s appointment of a new commercial director for the Eastern U.S. to drive adoption of Nociscan. Posts on X suggest optimism about this move, with some noting increased demand tied to ongoing clinical trials. This development has added to the positive buzz around the stock.
Note: This discussion summary was generated from an AI condensation of post data.
Aclarion, Inc. Insider Trading Activity
Aclarion, Inc. insiders have traded $ACON stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ACON stock by insiders over the last 6 months:
- BRENT NESS (Chief Executive Officer) purchased 10 shares for an estimated $62
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Aclarion, Inc. Revenue
Aclarion, Inc. had revenues of $18.9K in Q3 2025. This is an increase of 31.48% from the same period in the prior year.
You can track ACON financials on Quiver Quantitative's ACON stock page.
Aclarion, Inc. Hedge Fund Activity
We have seen 5 institutional investors add shares of Aclarion, Inc. stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DRW SECURITIES, LLC added 11,575 shares (+inf%) to their portfolio in Q3 2025, for an estimated $86,812
- CAPTRUST FINANCIAL ADVISORS added 10,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $75,000
- UBS GROUP AG removed 1,729 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $12,967
- TOWER RESEARCH CAPITAL LLC (TRC) added 506 shares (+674.7%) to their portfolio in Q3 2025, for an estimated $3,795
- BNP PARIBAS FINANCIAL MARKETS added 230 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,725
- MORGAN STANLEY removed 5 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $37
- CITIGROUP INC added 1 shares (+inf%) to their portfolio in Q3 2025, for an estimated $7
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Aclarion, Inc. Analyst Ratings
Wall Street analysts have issued reports on $ACON in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Ascendiant Capital issued a "Buy" rating on 11/20/2025
To track analyst ratings and price targets for Aclarion, Inc., check out Quiver Quantitative's $ACON forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
